During tumor progression, blocking PD-1 pathway leads to providing proliferative burst of (transitory) effector-like CD8 T cells from stem-like CD8 T cells, which subsequently differentiate into effector-like CD8+ T cells. Here, CD8A is linked to neoplasm.